Prothena | PRTA - Sales Revenues

Prothena reported $1.52M in Sales Revenues for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Sales Change
Akebia Therapeutics AKBA:US USD 55.18M 6.22M
ALKERMES ALKS:US USD 304.67M 52.32M
Amgen AMGN:US USD 6.84B 187M
Biogen BIIB:US USD 2.54B 35.5M
Bluebird Bio BLUE:US USD 71K 1.45M
Exelixis EXEL:US USD 423.92M 12.18M
Neurocrine Biosciences NBIX:US USD 412M 24.1M
Regeneron Pharmaceuticals REGN:US USD 3.41B 478.2M
Seattle Genetics SGEN:US USD 528.15M 17.85M
Ultragenyx Pharmaceutical RARE:US USD 103.35M 12.64M
Vertex Pharmaceuticals VRTX:US USD 2.3B 31.6M
YTE INCY:US USD 926.7M 103.4M